(Courtesy photo/drugtopics.com)

As a result of pressure from the Trump administration to move forward more quickly for a remedy, the Food and Drug Administration has developed an emergency authorization strategy to treat Covid-19 patients with convalescent plasma.
The convalescent plasma, which is made using blood from people who have recovered from coronavirus infections, has been used to treat more than 70,000 Covid-19 patients. FDA findings also state that the “known and potential benefits of the product outweigh the known and potential risks.”
While trials continue to be underway, early studies have also shown promise despite arguments by some health experts that data from randomized, placebo-controlled clinical trials are needed before it can be determined that the treatment is effective against Covid-19.

Leave a comment

Your email address will not be published. Required fields are marked *